[Federal Register Volume 63, Number 22 (Tuesday, February 3, 1998)]
[Notices]
[Page 5565]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-2562]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Coexclusive License: Vaccines for Dengue and
Other Flaviviruses
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH),
Department of Health and Human Services, is comtemplating the grant of
a limited field of use coexclusive world-wide license to practice the
invention embodied in U.S. Patent No. 5,494,671, issued February 27,
1996 (U.S. Patent Application Serial No. 07/747,785, filed August 20,
1991), entitled ``C-Terminally Truncated Dengue and Japanese
Encephalitis Virus Envelope Proteins'' to SmithKline Beecham Biological
of Rixensart, Belgium. Publication of this notice should be considered
a modification of an earlier notice (62 FR 5836, Feb. 7, 1997). The
patent rights in this invention have been assigned to the United States
of America.
DATES: Only written comments and/or applications for a license which
are received by NIH on or before April 6, 1998.
ADDRESSES: Requests for a copy of this issued patent, inquiries,
comments, and other materials relating to the contemplated license
should be directed to: Carol A. Salata, Technology Licensing
Specialist, Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804;
Telephone: (301) 496-7735 ext 232; Facsimile: (301) 402-0220; E-mail:
[email protected].
SUPPLEMENTARY INFORMATION: The patent describes the use of C-terminally
truncated flavivirus envelope proteins in vaccines against flavivirus
infections. The inventions also relates to recombinant viruses which
encode the truncated protein and to host cells infected therewith.
The prospective coexclusive license will be royalty-bearing and
will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR
404.7. It is anticipated that this license may be limited to the field
of subunit vaccines against Dengue and Japanese Encephalitis produced
in prokaryotic or eukaryotic cells. This license will not include live
virus, killed virus or DNA-based vaccines or the use of vaccinia virus
as a vector, or immunogen.
This prospective coexclusive license may be granted unless within
60 days from the date of this published notice, NIH receives written
evidence and argument that establishes that the grant of the license
would not be consistent with the requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license filed in response to this notice will be
treated as objections to the grant of the contemplated license.
Comments and objections submitted in response to this notice will not
be made available for public inspection, and, to the extent permitted
by law, will not be released under the Freedom of Information Act, 5
U.S.C. 552.
Dated: January 23, 1998.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 98-2562 Filed 2-2-98; 8:45 am]
BILLING CODE 4140-01-M